The aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.
Read moreThe subscription-style payment model for antibiotics announced by NICE in April 2022 will be capped ...
Read moreThe Access Consortium is made up of regulatory authorities including the UK, Australia, Canada, Sing...
Read moreDurvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...
Read moreIntroduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...
Read moreAccording to the ABPI, over the last 20 years, 82% of technology appraisal recommendations have been...
Read moreThe UK looks set to become the first country in the world to use a subscription-style payment model ...
Read moreIntroduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...
Read moreThe draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...
Read morePatients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...
Read more